Corticosteroids for severe sepsis: an evidence-based guide for physicians by Djillali Annane
REVIEW Open Access
Corticosteroids for severe sepsis: an evidence-
based guide for physicians
Djillali Annane
Abstract
Septic shock is characterized by uncontrolled systemic inflammation that contributes to the progression of organ
failures and eventually death. There is now ample evidence that the inability of the host to mount an appropriate
hypothalamic-pituitary and adrenal axis response plays a major in overwhelming systemic inflammation during
infections. Proinflammatory mediators released in the inflamed sites oppose to the anti-inflammatory response, an
effect that may be reversed by exogenous corticosteroids. With sepsis, via nongenomic and genomic effects,
corticosteroids restore cardiovascular homeostasis, terminate systemic and tissue inflammation, restore organ
function, and prevent death. These effects of corticosteroids have been consistently found in animal studies and in
most recent frequentist and Bayesian meta-analyses. Corticosteroids should be initiated only in patients with sepsis
who require 0.5 μg/kg per minute or more of norepinephrine and should be continued for 5 to 7 days except in
patients with poor hemodynamic response after 2 days of corticosteroids and with a cortisol increment of more
than 250 nmol/L after a standard adrenocorticotropin hormone (ACTH) test. Hydrocortisone should be given at a
daily dose of 200 mg and preferably combined to enteral fludrocortisone at a dose of 50 μg. Blood glucose levels
should be kept below 150 mg/dL.
Introduction
More than half a century after the first randomized,
controlled trial on corticosteroids for severe infection
[1], there is a broad use of corticosteroids by physicians
worldwide despite an amazing contradiction between
experts on their benefit-to-risk ratio. Among the various
factors that influence physician’s practice, one of the
most important is the positive or negative physician’s
own experience with a drug. The broad and longstand-
ing adoption of corticosteroids to treat severe infections
likely relies on the prompt reversal often seen at the
bedside of life-threatening complications, such as shock
and respiratory failure. The current controversy among
experts on this topic is not fuelled by new scientific data
but rather by distorting differently the reality. This cur-
rent review was designed to provide readers with a clear
and fair evaluation of the rationale for using corticoster-
oids and with evidence-based decision tree for whom to
treat, when, and how.
Rationale for using corticosteroids
Evidence for overactivity of proinflammatory pathways
relative to endogenous glucocorticoids activity
It is generally accepted that uncontrolled systemic inflam-
mation is the hallmark of severe sepsis and the main con-
tributor for the progression of organ dysfunction and
death [2]. Host control of inflammation involves a com-
plex interaction between the neuroendocrine and the
immune system [3,4]. At the cellular level, two very bio-
active systems tightly interact to maintain homeostasis.
The nuclear factor kappa B (NF-B) system promotes the
release of proinflammatory mediators, whereas the gluco-
corticoid-glucocorticoid receptor alpha (G-GRa) complex
inhibits inflammation [5]. These two systems are found in
all cells and, at rest, are inactivated; NF-B by its natural
inhibitor inhibitory factor kappa B (I-B) and the G-GRa
complex by a shift from the isoform alpha to the isoform
beta. As long as these two systems are equally counteract-
ing each other, homeostasis is preserved. Any imbalance
favoring NF-B bioactivity will results in uncontrolled
inflammation. There is ample evidence that such an imbal-
ance may occur in conditions of sustained stress. It was
shown that severe surgical stress, such as thoracoabdom-
inal surgery, resulted in postoperative relative adrenal
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insufficiency and subsequent high circulating levels of
proinflammatory mediators and development of organ
dysfunction [6]. Very similar findings have been reported
for trauma patients, after cardiac or liver surgery [7-9].
The so-called relative adrenal insufficiency contributes to
progression of critical illness and eventually to death in
both children and adults [10,11]. More specifically, in
patients with persistent acute respiratory distress syn-
drome [12] or septic shock [13], overactivity of NF-B
relative to the G-GRa complex contributes damaging
cells, tissues, and organs. The mechanisms behind critical
illness-induced adrenal insufficiency have been detailed
elsewhere [14]. Briefly, apart from drugs altering cortisol
metabolism and anatomical damages to the hypothalamic
pituitary adrenal axis, cytokine-induced overactivity of the
inducible isoform of nitric oxide synthase (iNOS) triggered
neuroendocrine cells apoptosis and caused ACTH and
glucocorticoid resistance. Critically ill survivors commonly
resumed a normal endocrine function weeks to months
after hospital discharge.
Glucocorticoids molecular mechanisms of action perfectly
fit to the pathomechanism of sepsis
Glucocorticoids exert their effects through nongenomic
and genomic effects. During the few minutes after expo-
sure to glucocorticoids occur the nongenomic effects,
including decreased platelets aggregation, cell adhesions
and intracellular phosphotyrosine kinases, and increased
annexin 1 externalization [15,16]. These effects likely
result from interaction of the glucocorticoid and specific
membrane sites [17]. The genomic effects are commonly
described as transrepression and transactivation effects
[18]. The transrepression effects are considered indirect
genomic effects. Indeed, they occur during the few
hours after exposure to a glucocorticoid and result from
physical interaction between the monomeric G-GRa
complexes and NF-B and AP-1. Then, the nuclear
transcription factors are sequestrated in the cytosol and
cannot enter the nucleus, preventing the reading of
genes encoding for most if not all proinflammatory
mediators. The transactivation effects are seen as direct
genomic effects. They require a few days of exposure to
a glucocorticoid. Indeed, conformational changes are
needed with dimerization of the G-GRa complex, which
then can enter to the nucleus and interact with gluco-
corticoid-responsive elements part of genes encoding for
regulators of termination of inflammation. Subsequently,
key anti-inflammatory factors are upregulated, including
phagocytosis, chemokinesis, and antioxidative processes.
It is now commonly accepted that the net effect of glu-
cocorticoids on immune cells is reprogrammation rather
than inhibition [19]. Indeed, studies using microarray
tools demonstrated that there are much more upregu-
lated than downregulated genes after exposure to a
glucocorticoid. More recent works have confirmed that
glucocorticoids induce specific activated, anti-inflamma-
tory monocytes subtypes that migrate quickly to the
inflamed tissues [20]. Glucocorticoids prolonged the sur-
vival of this subtype of monocytes via an A3 adenosine
receptor triggered anti-apoptotic effects [21]. Obviously,
these molecular mechanisms of action of glucocorticoids
are very well appropriate to counteract the uncontrolled
inflammation that characterized sepsis.
Glucocorticoids restore cardiovascular homeostasis in
sepsis
The mechanisms behind the cardiovascular effects of cor-
ticosteroids are not well understood. Corticosteroids
induce sodium retention via both mineralocorticoid and
glucocorticoid receptors. Thereby, corticosteroids will
contribute to correct the hypovolemia that characterizes
the early phase of sepsis. In addition, by favoring sodium
and water accumulation in blood vessels’ wall, corticos-
teroid will contribute to increase systemic vascular resis-
tance. As detailed elsewhere [22], corticosteroids restore
within minutes to hours via nongenomic effects vessels
sensitivity to alpha agonist with subsequent increase in
mean arterial pressure and systemic vascular resistance.
They may interfere with activation of ATP-dependent K+
channel [23]. The enhanced responsiveness to catechola-
mines is maintained over days via corticosteroids transre-
pression of genes encoding for iNOS and cyclooxygenase
II. The restoration of vascular responsiveness to vasopres-
sor is likely correlated to the intensity of the imbalance
between NF-B and G-GRa complex activity. Nonre-
sponders to 250-μg ACTH test, i.e., having cortisol incre-
ment of <250 nmol/L, have a more marked improvement
in hemodynamics following intravenous bolus of hydro-
cortisone [24,25]. There was a very strong correlation
between the peak cortisol after ACTH and the peak
increase in mean arterial pressure after 50 mg of intrave-
nous hydrocortisone in norepinephrine-treated septic
shock [24]. Accordingly, initiation of corticosteroids shor-
tened the duration of vasopressor dependency in septic
shock patients, and increased the chance of be weaned
off of catecholamines by 35% [26]. Of note, premature
interruption of corticosteroids, i.e., stopping treatment
after 72 hours may cause rebound in inflammation and
worsening of hemodynamic status [27]. Corticosteroids
have little if no effect on pulmonary circulation or cardiac
index [27]. Treatment with moderate doses of hydrocorti-
sone increased capillary density and perfusion in patients
with septic shock [28]. These favorable effects on the
microcirculation occurred within 1 hour after hydrocorti-
sone administration and may likely result from upregula-
tion of the endothelial isoform of the nitric oxide
synthase via a mitogen-activated protein kinase/Akt-
dependent pathway [29]. Finally, corticosteroids may
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favor the restoration of the physiologic fluctuations in the
cardiovascular system [30].
Corticosteroids restore organs function and decrease
intensive care unit length of stay of patients with sepsis
Corticosteroids may both prevent organ failure and
reduce the intensity and number of organ dysfunction
by reducing tissue inflammation and triggering tissue
repair and by improving tissue perfusion. For example,
in patients with acute respiratory distress syndrome,
exogenous administration of corticosteroids completely
blocked NF-B in the lung [12]. In patients with septic
shock, glucocorticoids inhibited the release of tumor
necrosis factor from vascular tissues and smooth mus-
cles [31]. In addition, treatment with hydrocortisone
fully inhibited NF-B activity in peripheral mononuclear
cells by day 5 of treatment [13]. Corticosteroids have
been shown to suppress renal iNOS activity after endo-
toxemia to prevent hypoxic injuries to the cortex, to
improve renal oxygen delivery, and finally to restore
renal oxygen consumption [32]. Likewise, in patients
with septic shock, corticosteroids improved permeability
of the glomerular endothelium [33] and normalized free
water clearance and renal sodium excretion (Djillali
Annane, personal communication). The favorable effects
of corticosteroids on organ perfusion also have been
shown for the heart [29] and brain [34,35]. A meta-ana-
lysis of five randomized trials demonstrated a strong
reduction in the SOFA score at 1 week after randomiza-
tion (weighted mean difference, -1.47 [-2.01, -0.92], P <
0.00001, with no heterogeneity in the results: I2 = 2%)
[36]. Corticosteroids favorably affected cardiovascular,
lung, liver, and renal functions. Because patients treated
with corticosteroids are rapidly weaned off vasopressor
therapy and mechanical ventilation, they are discharged
much earlier from the intensive care unit. Indeed, In a
meta-analysis of eight septic shock trials, corticosteroids
decreased by 4.5 days on average intensive care unit
length of stay (weighted mean difference: -4.49: -7.04 to
-1.94, P = 0.00055; and I2 = 0%).
Corticosteroids and survival from sepsis
Whereas corticosteroids invariably improved survival in
endotoxinic or septic animals, clinical studies have
reported conflicting results. Nevertheless, recent critical
analyses of the available randomized trials have sug-
gested in both frequentist [26,36,37] and Bayesian [38]
approaches that low-to-moderate doses of corticoster-
oids improved survival, whereas a short course with
high-dose corticosteroids had no or harmful effects. In
the two frequentist meta-analyses, this treatment was
associated with a risk ratio (RR) for 28-day mortality of
0.84 (n = 12 trials, I2 = 15%; 95% confidence interval
(CI), 0.72-0.97; P = 0.02) [26] and an odds ratio (OR)
for death of 0.64 (n = 12, I2 = 25%; 95% CI, 0.45-0.93;
P = 0.02) [37]. In the Bayesian meta-analysis, the
authors computed the probability of OR for death as >1
[38]. They included nine trials of low-to-moderate doses
of corticosteroids (<1,000 mg per day of hydrocortisone
or equivalent). The mortality probability (i.e., that OR
was >1 with corticosteroids) was 20.4%. There was
strong heterogeneity in the results due to inclusion of
one old trial with poor methodological quality, including
both children and adults and with a short course (<3
days) of hydrocortisone [39]. When excluding this out-
lier, the mortality probability was only 5.8%, suggestive
of survival benefit from low-to-moderate doses of corti-
costeroids. Because there is mega-trial of corticosteroids
for sepsis, the best evidence is the one provided by
high-quality systematic reviews and meta-analysis, sug-
gesting survival benefit from prolonged treatment with
low-to-moderate dose of corticosteroids.
Corticosteroids safety in sepsis
The recent meta-analyses of corticosteroids for severe
sepsis consistently did not find any increase in the risk
of superinfection, gastroduodenal bleeding, or muscle
weakness [2,36-38]. There often is a misunderstanding
of the findings from CORTICUS [40]. In CORTICUS,
hydrocortisone was not associated with an increase in
the rate of infection in the lung, abdominal, urinary
tract, wound tissues, or the rate of catheter-related
infection of primary septicemia. Hydrocortisone-treated
patients had a higher rate of shock relapse, which may
not necessarily be related to documented new infections.
Use of Corticosteroids in practice: the “Who,”
“When,” and “How”
Optimal target population for corticosteroids
In this review, we will not consider the use of corticos-
teroids in specific infections, such as bacterial or tuber-
culosis meningitis, severe typhoid fever, or Pneumocystis
carinii infections in the immune-compromised patient.
A necessary condition to initiate corticosteroids in
patients with severe infections is the need for vasopres-
sor therapy. Moreover, the recent meta-analyses found a
strong and negative correlation between the severity of
sepsis and the relative risk of dying [36-38]. The meta-
regression analysis suggested that low-to-moderate
doses of corticosteroids are more likely to improve sur-
vival in patients with a baseline risk of death of 44% or
more. One of the major differences between the French
Ger-Inf-05 study [25] and CORTICUS [40] was baseline
severity of septic shock. More specifically, in the former
trial patients had to require dose of vasopressors that
were roughly twice greater than in CORTICUS (on aver-
age 1.1 μg/kg/min vs. 0.5 μg/kg/min of norepinephrine).
Of note, analysis of the subgroup of CORTICUS
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patients (n = 126) who met the same entry criteria than
those requested in the French Ger-Inf-05 trial found
survival benefits that were very consistent with findings
of the French trial. Indeed, 63 of 126 patients died at
28 days after randomization. There were 31 of 69 (45%)
deaths in the hydrocortisone-treated group and 32 of 57
(56%) in the placebo group, corresponding to a -11%
absolute reduction in 28-day mortality. In practice, cor-
ticosteroids should be initiated in patients with sepsis
requiring >0.5 μg/kg/min of norepinephrine or equiva-
lent (Figure 1).
None of the recent meta-analysis found differences in
treatment benefits in nonresponders versus responders
to the ACTH test [3-38]. However, in the French Ger-
Inf-05 trial [25], only nonresponders to the 250-μg
ACTH test (cortisol increment < 250 nmol/L) drew ben-
efit from corticosteroids. Whereas in CORTICUS pri-
mary analysis, there was no interaction between
treatment effects and the results of the ACTH test [40],
in the subpopulation mimicking the French trial popula-
tion, hydrocortisone significantly decreased mortality in
the nonresponders (hazards ratio (HR) = 0.45; 95% CI,
0.21-0.93) and had no effect in the responders (HR =
0.9; 95% CI, 0.45-1.78). Thus, it is this author’s opinion
that an ACTH test should be performed when initiating
corticosteroids. The results of diagnostic tests should be
taken into account for the decision to stop or continue
treatment (see below).
When corticosteroids should be initiated? And stopped?
Animal experiments have demonstrated that baboons
challenged with a lethal dose of endotoxin had a greater
survival chance when corticosteroids were initiated within
the first 4 hours, even though delayed treatment was asso-
ciated with better survival rates than controls [41]. Five
randomized trials investigated the effects of low-to-moder-
ate doses of corticosteroids when initiated within the 24
hours of onset of severe sepsis [25,42-46]. There were 118
deaths among the 222 corticosteroids-treated patients and
139 deaths among the 223 controls (RR = 0.85; 95% CI,
0.73-0.99; P = 0.03). There was no heterogeneity across
the studies (I2 = 0%). In contrast, in five studies with a
time window of up to 72 hours [40,47-49], corticosteroids
had no effect on survival (RR = 0.72; 95% CI, 0.48-1.1; P =
0.13) and there was some heterogeneity across the studies
(I2 = 49%). Thus, based on findings from animal experi-
ments and clinical trials, corticosteroids should be initiated
within the first 24 hours of septic shock.
Recommendations from experts suggest that treatment
with corticosteroids should be weaned off over 3 to
6 days after 5 days of treatment at full dose [50,51]. Due
to the genomic nature of sustained corticosteroids
effects, treatment should be prolonged for several days.
Meta-regression in a recent meta-analysis suggested that
the duration of treatment at full dose is a strong predic-
tor of survival benefit from corticosteroids with the
“neutrality line” being crossed by the regression line for
time equal to 120 hours arguing for maintaining treat-
ment at full dose for at least 5 days [26,36]. In this
meta-analysis, there was no evidence for better survival
rates in studies with versus without tapering. It is this
author’s opinion that corticosteroids should be stopped
in patients whose vasopressor dependency has not
improved after 2 days of treatment and are responders
to the 250-μg ACTH test.
How should corticosteroids be given?
As highlighted in the first part of this review, the ratio-
nale for using corticosteroids in septic shock relies on the
concept of critical illness associated corticosteroids insuf-
ficiency [51]. Hydrocortisone, the natural hormone,
should be preferred to synthetic corticosteroids. The
commonly accepted dose is on average 200 mg per day.
A recent meta-analysis demonstrated that the lower the
corticosteroids dose the greater the response to treat-
ment [26,36]. Hydrocortisone may be given as boluses or
as a continuous infusion. Whereas a continuous infusion
may be associated with less glucose variability [52], it also
may favor adrenal insufficiency after withdrawal of corti-
costeroids. A recent randomized trial of corticosteroid-
treated septic shock found no evidence for a benefit of
normalizing blood glucose levels versus maintaining
levels <150 mg/dL [53]. The adjunction of fludrocorti-
sone to hydrocortisone remains controversial. In a recent
randomized trial, there was a -3% nonstatistically signifi-
cant absolute reduction in mortality with hydrocortisone
plus fludrocortisone versus hydrocortisone alone. How-
ever, this trial was not powered for this analysis, there
was no fludrocortisone placebo, and the study was not
blinded. Thus, due to the fact that the French Ger-Inf-05
trial has tested the combination of hydrocortisone and
fludrocortisones, it is still this author’s opinion that flu-
drocortisones should be given via the nasogastric tube at
a dose of 50 μg per day.
Conclusions
There is a strong biological rationale to support the use
of low-to-moderate doses of corticosteroids for at least
5 days before tapering. Animal studies and recent fre-
quentists or Bayesian meta-analyses consistently have
demonstrated survival benefit with this treatment parti-
cularly when given to the sickest patients, i.e., those
who require 0.5 μg/kg per minute or more of norepi-
nephrine. Treatment should be initiated within the first
24 hours and should consist of both hydrocortisone and
fludrocortisone.
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